HYDRONIDONE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C12H11NO2
Molecular Weight	201.2212
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CC1=CN(C(=O)C=C1)C2=CC=C(O)C=C2

InChI

InChIKey=NETTXQJYJRFTFS-UHFFFAOYSA-N

InChI=1S/C12H11NO2/c1-9-2-7-12(15)13(8-9)10-3-5-11(14)6-4-10/h2-8,14H,1H3

HIDE SMILES / InChI

Molecular Formula	C12H11NO2
Molecular Weight	201.2212
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

F-351 (Hydronidone), a pyridine derivative, is a non-steroidal antiinflammatory drug. It inhibits hepatic stellate cell proliferation and also the TGF-β signaling pathway. Shanghai Genomics is developing F-351 for the treatment of liver fibrosis induced by HBV chronic hepatitis (HBV). For additional indications, F-351 has the potential to be further developed for Non-alcoholic steatohepatitis (NASH) liver disease, Non-alcoholic fatty liver disease (NAFLD) and chronic kidney failure.

Originator

Approval Year

Targets

Targets

Primary Target	Pharmacology	Condition	Potency
Fibroblast growth factor 1	Inhibitor 8,297

PubMed

Title	Date	PubMed
No data available in table

Patents

Sample Use Guides

In Vivo Use Guide

A randomized, dose-escalating, first-in-human study was conducted in 88 subjects. Five cohorts of 34 subjects received a single dose of hydronidone capsules at 15-120 mg, and two cohorts of 12 subjects received 90 and 120 mg of hydronidone thrice daily for 7 days, and six subjects received 60 mg of hydronidone thrice daily for 28 days to assess the safety and tolerability. In 36 subjects, hydronidone pharmacokinetics were investigated following oral administration of single (30, 60, and 120 mg) and multiple (60 mg, thrice daily) doses of hydronidone.

Route of Administration: Oral

Substance Class	Chemical
Record UNII	RXQ128313W
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

HYDRONIDONE

Common Name

English

F-351

Code

English

F 351

Code

English

1-(4-HYDROXYPHENYL)-5-METHYLPYRIDIN-2(1H)-ONE

Systematic Name

English

N-(4-HYDROXYPHENYL)-5-METHYL-2-PYRIDONE

Systematic Name

English

Showing 1 to 5 of 5 entries

Previous1Next

Show entries

Code System

Code

Type

Description

PUBCHEM

11217901

PRIMARY

DRUG BANK

DB06299

PRIMARY

FDA UNII

RXQ128313W

PRIMARY

EPA CompTox

DTXSID40459058

PRIMARY

CAS

851518-71-3

PRIMARY

Showing 1 to 5 of 5 entries

Previous1Next

Show entries

Related Record

Type

Details


					RXQ128313W

HYDRONIDONE

ACTIVE MOIETY

Comments:

Drug: Hydronidone; Indication: Hepatic fibrosis; Focus: Therapeutic Use; Sponsor: Shanghai Genomics; Most Recent Event: 21 Jul 2015 New trial record


					RXQ128313W

HYDRONIDONE

ACTIVE MOIETY

Comments:

The U.S. Food and Drug Administration (FDA) is warning about several safety issues with the entire class of opioid pain medicines. These safety risks are potentially harmful interactions with numerous other medications, problems with the adrenal glands, and decreased sex hormone levels. We are requiring changes to the labels of all opioid drugs to warn about these risks.


					RXQ128313W

HYDRONIDONE

ACTIVE MOIETY

Comments:

ISSUE: FDA is warning about several safety issues with the entire class of opioid pain medicines. See the http://www.fda.gov/Drugs/DrugSafety/ucm489676.htm for a complete listing. These safety risks are potentially harmful interactions with numerous other medications, problems with the adrenal glands, and decreased sex hormone levels. We are requiring changes to the labels of all opioid drugs to warn about these risks.

Showing 1 to 3 of 3 entries

Previous1Next